Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Lomustine-Induced Thrombocytopenia in Glioblastoma
NCT04933942Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of romiplostim in Thrombocytopenia, sponsored by European Organisation for Research and Treatment of Cancer. Planned start Sep 2022; status: withdrawn.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04933942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933942.